Transurethral vaporization of prostate for BPH patients with cardiovascular and cerebrovascular diseases

SU Qing-Hua,ZHAN Hai-Lun,CAI Yu-Bin,LI Jian,GAO Xin
DOI: https://doi.org/10.3969/j.issn.1007-1989.2008.07.016
2008-01-01
Abstract:[Objective] To evaluate the safety and efficacy of transurethral vaporization of the prostate (TUVP) for benign prostatic hyperplasia(BPH) patients with cardiovascular and cerebrovascular diseases. [Methods] TUVP was undertaken for 63 BPH patients with cardiovascular and cerebrovascular diseases. The irrigation was usually 5% mannitol, but 5% glucose in patients with renal dysfunction. If the weight of prostate was less than 75 g, the prostate were resected completely. If the weight of prostate was higher than 75 g and the patients were elder than 80 years, the prostate were resected partially. The I-PSS before and after operation were measured. The safety and efficacy of operation were evaluated. [Results] All the 63 cases were able to bear TUVP securely. The operation time was 28~104 minutes with the mean of 52 minutes. The emiction was unobstructed after the catheter was removed three to five days after operation. The I-PSS dropped from 30.3 to 11.8, Qmax rose from 6.5 to 16.5 mL/s after three months follow-up, and there was a significant difference (P <0.01). Two cases had perforation during the treatment of bladder neck and developed to transurethal resection syndrome (TURS). Three cases had presymptoms of TURS and received treatments in time. One case with cerebral infarction had severe postoperative hemorrhage because anticoagulant drug was taken for a long time, and had to take TUVP again to control hemorrhage. [Conclusions] It is suggested that TUVP is effective and safe to deal with BPH patients with cardiovascular and cerebrovascular diseases.
What problem does this paper attempt to address?